Gilead Sciences and the associated logos are trademarks of Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company dedicated to advancing transformative therapies in areas of significant unmet medical need, with a strong legacy in liver disease. Gilead is recognized as a global leader in the development of antiviral therapies and has pioneered innovative treatments that have revolutionized care for viral hepatitis, particularly hepatitis B (HBV) and hepatitis C (HCV), helping to dramatically reduce the global disease burden.

Gilead’s portfolio includes groundbreaking, once-daily oral regimens such as Vemlidy® (tenofovir alafenamide) for chronic HBV infection and Epclusa® (sofosbuvir/velpatasvir) and Harvoni® (ledipasvir/sofosbuvir) for chronic HCV—therapies that have set new standards for efficacy, safety, and simplicity. These direct-acting antivirals (DAAs) offer high cure rates with shorter treatment durations, supporting global hepatitis elimination goals.

Building on this expertise, Gilead is also advancing a robust pipeline targeting emerging areas of liver disease, including MASH (Metabolic dysfunction-associated steatohepatitis) and MASLD (Metabolic dysfunction-associated steatotic liver disease). Investigational candidates such as seladelpar and alofisel are designed to modulate key inflammatory and fibrotic pathways in chronic liver injury, with the goal of halting disease progression and restoring liver function. These therapies are part of a broader strategy to address the systemic nature of liver disease and its metabolic and immune components.

Gilead recognizes that liver disease disproportionately affects underserved populations worldwide and continues to invest in access and equity initiatives to ensure life-saving therapies reach those most in need. Through strategic collaborations, biomarker-driven clinical development, and real-world evidence generation, Gilead remains at the forefront of liver care innovation.

With a continued focus on virology, inflammation, and fibrosis, Gilead Sciences is committed to delivering a new generation of therapies that can transform the lives of individuals living with chronic and progressive liver disease.